To Top

Content Filter


2749 Articles available
Drug Development

Addressing the Challenges and Opportunities Presented by Advanced Therapies

PAO-M01-19-NI_CL-001
Lyophilization

Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI

PR-M01-19-NI-052
Robotics

The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028

PR-M01-19-NI-043
Expression System

Fujifilm Announces the Launch of Its Next Generation Apollo™ X Advanced Mammalian Expression System

PR-M01-19-NI-042
Myopia

SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

PR-M01-19-NI-040
Precision Diagnostics

Pillar Biosciences Enters Strategic Partnership with China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

PR-M01-19-NI-041
Partnership

Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India

PR-M01-19-NI-039
Investment

New Opioid-alternative Raises $3.25 Million for Phase I Trials

PR-M01-19-NI-037
Announcement

A Path Forward for Increasing Kidney Transplantation

PR-M01-19-NI-036
ALS Research

Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression

PR-M01-19-NI-035
Hematology/Oncology

Blood Cancer Therapeutics: Global Markets to 2023

PR-M01-19-NI-034
Medical Device

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

PR-M01-19-NI-033
RNA Splicing

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

PR-M01-19-NI-032
Immuno-oncology

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PR-M01-19-NI-031
Leadership

AstraZeneca Announces Organizational Changes

PR-M01-19-NI-029
Approval

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

PR-M01-19-NI-028
Drug Development

Researchers Identify Potential Approach for Treating the Toughest Breast Cancer

PAO-M01-19-NI-013
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

PAO-M01-19-NI-012
Investment

Swiss AI Firm Raises Funds for Entry into U.S.

PAO-M01-19-NI-011
R&D

Allergan Establishes R&D Group in Massachusetts

PAO-M01-19-NI-010
Inhalation

FDA Approves First Inhaler with Built-in Sensors

PAO-M01-19-NI-009
Facility

DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

PR-M01-19-NI-036
Realignment

Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities

PR-M01-19-NI-024
Immuno-Oncology

PrimeVax Immuno-Oncology Receives IND Permission From FDA

PR-M01-19-NI-026
Investment

Antengene Benefits from Second-Round Financing

PAO-M01-19-NI-008
Investment

Biotech Company Stealth BioTherapeutics Files for IPO

PAO-M01-19-NI-007
Clinical Trials

Initial Positive Results Lead to Expanded Cancer Trial

PAO-M01-19-NI-006
Cell and Gene Therapy

New Assays for Detecting Genomic Mutations Launched by Contextual Genomics

PAO-M01-19-NI-005
Investment

Vedanta Increases Investment

PAO-M01-19-NI-004
Drug Pricing

Drug Companies Raise Prices to Start New Year

PAO-M01-19-NI-003
FDA Approval

FDA Approves Parkinson’s Drug

PAO-M01-19-NI-002
M&A

Remembering the Details: Partnering with an Equipment Supplier During a Merger or Acquisition

PAO-M01-19-CL-001
Acquisition

Neogen Acquires Canadian Animal Genomics Laboratory

PR-M01-19-NI-011
Financial Results

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019

PR-M01-19-NI-010
J.P. Morgan Healthcare Conference

Grace Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR-M01-19-NI-009
Immuno-oncology

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

PR-M01-19-NI-023
FDA

PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration

PR-M01-19-NI-016
Drug Development

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

PR-M01-19-NI-013
Acquisition

Rentschler Biopharma Completes Acquisition of U.S. Manufacturing Site

PR-M01-19-NI-021
Announcement

Baltimore Biotech Earns International Recognition for Advanced Development and Manufacturing Facility

PR-M01-19-NI-020
Appointment

Brammer Bolsters Leadership Team and Announces Chief Quality Officer

PR-M01-19-NI-019
Immuno-oncology

Gilead Invests in Immuno-oncology

PAO-M01-19-NI-001
M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

PR-M01-19-NI-017
Announcement

Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR-M01-19-NI-006
Investment

China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering

PR-M01-19-NI-007
Investment

Connect Biopharmaceuticals Completes $55 Million Series B Financing to Accelerate Clinical Development of Novel Immune Modulators

PR-M01-19-NI-005
Leadership

AbbVie Announces Executive Leadership Changes

PR-M01-19-NI-003
Biosimilar

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

PR-M01-19-NI-002
Launch

Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering

PR-M01-19-NI-001
Oncology

Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for Head and Neck Cancer

PR-M12-18-NI-086
Market Prediction

Pneumatic Nebulizers Market Will Surge at 5.3% CAGR to Hit $875 Mn by 2024: Global Market Insights, Inc.

PR-M12-18-NI-083
Financing

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

PR-M12-18-NI-081
New Facility

Pall Opens Center of Excellence in Shanghai

PR-M12-18-NI-080
Advisory Board

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

PR-M12-18-NI-079
Acquisition

Bruker Completes the Acquisition of Alicona Imaging GmbH

PR-M12-18-NI-082
Drug Development

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

PR-M12-18-NI-076
Inflammation

IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body

PR-M12-18-NI-072
Appointment

AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

PR-M12-18-NI-074
Biomanufacturing Facility

LakePharma Announces its cGMP MicroBiomanufacturing Center is Now Operational

PR-M12-18-NI-073
Alzheimer's Disease

Public Supports NIH Grants for Alzheimer's Microbes, Reports Alzheimer's Germ Quest, Inc.

PR-M12-18-NI-071
Strategic Alliance

Ajinomoto and XL-protein Forge Strategic Alliance to Develop PASylated Therapeutics Applying the Corynex® Platform

PR-M12-18-NI-069
Opioid Dependency

Could the Opioid Epidemic Be Relieved by a Vaccine?

PAO-M12-18-NI-019
CRISPR

Gene Amplification Controls Obesity in Mice

PAO-M12-18-NI-018
New Facility

Sanofi to Consolidate Massachusetts Activities

PAO-M12-18-NI-017
Drug Development

AbbVie Exercises Option to License Parkinson’s Tech from BioArctic

PAO-M12-18-NI-015
Dementia

Single Gene Identified as Culprit in Early-Onset Dementia

PAO-M12-18-NI-016
Drug Approval

AstraZeneca and FibroGen Receive First Approval for Anemia Drug in China

PAO-M12-18-NI-014
Marketing

Partnership Initiates Fight to Regulate Lawsuit Ads Targeting “Bad Drugs”

PAO-M12-18-NI-013
Biologics

Rentschler Expands Capabilities in Biologics Contract Manufacturing

PAO-M12-18-NI-012
Quality

Continuous Quality is Essential in Parenteral Manufacturing

PAO-M12-18-CL-003
Biologics Manufacturing

AGC Triples U.S. Biopharmaceutical Production Capacity

PR-M12-18-NI-066
Market Prediction

Emerging Medical Device Market Expected to Exceed $400 Billion by 2023

PR-M12-18-NI-065
Patient Adherence

Sempre Health and UPMC Health Plan Expand Program that Improves Affordability and Adherence for Critical Medications

PR-M12-18-NI-064
Collaboration

Marken and TrakCel Collaborate to Serve Cell and Gene Trials

PR-M12-18-NI-087
Medical Device

Statement from Jeff Shuren, Director of the CDRH, on Updated Safety Communication About Rates of Duodenoscope Contamination from Preliminary Postmarket Data

PR-M12-18-NI-062
Surgical Robots

The global Surgical Robots Market is Projected to Reach 6.5 billion by 2023 from USD 3.9 billion in 2018 at a CAGR of 10.4%

PR-M12-18-NI-061
Public Offering

Biohaven Announces Proposed Public Offering of Common Shares

PR-M12-18-NI-060
Clinical Trial Patient Populations

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

PR-M12-18-NI-059
Cell Expansion

Cell Expansion Market to Reach US $26 Billion by 2024, Says TMR

PR-M12-18-NI-058
Investment

GenEdit Closes $8.5 million Series Seed Financing

PR-M12-18-NI-056
Approval

World-first Approval For Multiple Myeloma Drug APLIDIN(R)

PR-M12-18-NI-055
Drug Development

Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

PR-M12-18-NI-054
Acquisition

Therapix Biosciences Provides Update Regarding FSD Acquisition

PR-M12-18-NI-052
Presentation

Abbott to Present at J.P. Morgan Healthcare Conference

PR-M12-18-NI-051
Appointment

BiomX Appoints Sailaja Puttagunta as Chief Medical Officer

PR-M12-18-NI-048
FDA

XOSPATA® (gilteritinib) Available at Biologics by McKesson

PR-M12-18-NI-045
Pricing

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Expansion

NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem

PR-M12-18-NI-043
Financing

Impel NeuroPharma Closes $67.5 Million Series D Financing

PR-M12-18-NI-040
Immuno-Oncology

Immuno-oncology Development Trends and Opportunities

PR-M12-18-NI-038
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037
Financial Results

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

PR-M12-18-NI-036
Approval

Genentech Receives Additional Approval for Tecentriq

PAO-M12-18-NI-011
Appointment

Roche Exec Moves to Gilead

PAO-M12-18-NI-010
FDA

FDA Issues Draft Guidance for Companion Diagnostics

PAO-M12-18-NI-009
Spin-off Business

Mallinckrodt Spins off its Generics Business

PAO-M12-18-NI-005-11
Growth

WuXi AppTec Plans for Growth

PAO-M12-18-NI-005-10
Expansion

Investor Group Purchases 110-Acre Pharmaceutical Campus in Huntsville, Alabama

PR-M12-18-NI-047
M&A

Histo-Scientific Research Laboratories and Vet Path Services Merge

PR-M12-18-NI-046
Gene and Cell Therapy

PPD Expands GMP Lab Testing Capabilities for Biologics

PR-M12-18-NI-035
Stem Cells

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

PR-M12-18-NI-033
FDA Acceptance

FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis

PR-M12-18-NI-030
FDA Approval

Olympus Spiration® Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema

PR-M12-18-NI-029
Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028
Appointment

Sartorius Supervisory Board Appoints Two New Executive Board Members

PR-M12-18-NI-027
License Agreement

Ablexis Announces Licensing Agreement with Allogene Therapeutics

PR-M12-18-NI-026
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025
Obesity

The Anti-Obesity Drugs Market Will Register a CAGR of Almost 8% by 2023

PR-M12-18-NI-024
Chronic Migraine

Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.

PR-M12-18-NI-023